Ir para o conteúdo principal

Tyra Biosciences (NASDAQ: TYRA) — Perfil da empresa, notícias e dados financeiros

Logo de Tyra Biosciences
TYRA Tyra Biosciences
Tyra Biosciences primary media
Perfil da empresa

Tyra Biosciences

Tyra Biosciences (NASDAQ:TYRA) focuses on driving scientific innovation to address critical needs in the treatment of cancer and other diseases through precision medicine. With a keen eye on the development of targeted therapies, Tyra Biosciences is steadfast in its mission to discover and develop novel compounds that can potentially transform patient outcomes. The company harnesses a unique research and development approach that prioritizes the understanding of the molecular and cellular fabric of diseases, aiming to bring forth solutions that are both innovative and effective. Their projects span across a broad spectrum of oncology and genetic diseases, aiming to unlock new treatment avenues and improve quality of life for patients. Objective-wise, Tyra Biosciences is dedicated to advancing its pipeline of therapies from early-stage discovery through to clinical development, with the ultimate goal of achieving regulatory approval and commercial success.

Resumo

Public USParticipação acionária
2018Ano de fundação
51Funcionários
Carlsbad, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Carlsbad, US

Produtos e/ou serviços de Tyra Biosciences

  • Development of precision oncology therapies targeting genetically defined vulnerabilities.
  • Creation of small molecule drugs designed to overcome treatment resistance in cancer patients.
  • Advancement of a robust drug discovery platform utilizing a proprietary structure-based drug design.
  • Focus on therapy for FGFR (Fibroblast Growth Factor Receptor) mutations and fusions in various cancers.
  • Involvement in collaborative research and development partnerships to enhance cancer treatment options.
  • Provision of comprehensive biomarker and diagnostic strategies to personalize patient care.

equipe executiva do Tyra Biosciences

  • Todd HarrisCo-Founder, CEO, President & Director
  • Bhavesh AsharChief Operating Officer
  • Douglas WarnerChief Medical Officer
  • Daniel BensenCo-Founder & Chief Discovery Officer
  • Alan FuhrmanChief Financial Officer
  • Julia RuebVP of Finance & Principal Accounting Officer
  • Robert L. HudkinsChief Technology Officer
  • Ronald V. SwansonChief Scientific Officer
  • Ali D. FawazGeneral Counsel & Secretary
  • Sarah HonigSenior VP of Corporate Development & Strategy

Principais indicadores financeiros

Resultados divulgados pela Tyra Biosciences, em USD.

Cap. de mercado
1,5 bi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-2.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Tyra Biosciences
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-132,8 mi-119,9 mi
0-104,2 mi-86,5 mi
0-79,9 mi-69,1 mi
0-58,9 mi-51,7 mi